Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AtriCure (ATRC) Other Accumulated Expenses (2016 - 2025)

Historic Other Accumulated Expenses for AtriCure (ATRC) over the last 17 years, with Q3 2025 value amounting to $3.0 million.

  • AtriCure's Other Accumulated Expenses changed N/A to $3.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.0 million, marking a year-over-year change of. This contributed to the annual value of $2.8 million for FY2024, which is N/A changed from last year.
  • According to the latest figures from Q3 2025, AtriCure's Other Accumulated Expenses is $3.0 million.
  • Over the past 5 years, AtriCure's Other Accumulated Expenses peaked at $20.7 million during Q3 2023, and registered a low of $1.8 million during Q4 2021.
  • Moreover, its 5-year median value for Other Accumulated Expenses was $8.1 million (2022), whereas its average is $9.7 million.
  • Data for AtriCure's Other Accumulated Expenses shows a peak YoY increase of 26823.46% (in 2021) and a maximum YoY decrease of 7913.75% (in 2021) over the last 5 years.
  • AtriCure's Other Accumulated Expenses (Quarter) stood at $1.8 million in 2021, then soared by 211.62% to $5.5 million in 2022, then surged by 278.33% to $20.7 million in 2023, then plummeted by 86.45% to $2.8 million in 2024, then increased by 6.88% to $3.0 million in 2025.
  • Its last three reported values are $3.0 million in Q3 2025, $2.8 million for Q4 2024, and $20.7 million during Q3 2023.